Skip to content

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

Press Releases

Select Year
Search

Found 145 Results

September 6, 2022

Cognition Therapeutics Announces Participation in September Investment Conferences

August 9, 2022

Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 4, 2022

Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes

August 3, 2022

Cognition Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

July 19, 2022

Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease

June 23, 2022

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

June 8, 2022

Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference

«...12 131415 16...20...»

Investor Relations Contact

Cognition Therapeutics
info@cogrx.com

Mikey Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Email Alerts

Email

SEC Filings

Press Releases

End of Day Stock Quote

I accept the Privacy Policy

Loading...

Terms of Use
Privacy Policy
Careers

FCOI Policy
Contact us

Copyright© 2024 Cognition Therapeutics All rights reserved

Scroll to Top